Supply chains are tested daily for stability, from facing potential pandemic-style disruption to geopolitical volatility. They must be able to support critical assets; in defense, this includes lives.

In biotechnology, timing is everything. Whether advancing a novel therapy or scaling a platform, companies often reach a pivotal point: go public or sell. Increasingly, biotech executives are choosing ...